Skip to content

Ketamine research published in 2016

93 studies whose primary subject is ketamine were published in 2016, up from 56 in 2015. Newest first. Back to the ketamine overview

Studies

Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder

The Journal of Clinical Psychiatry December 6, 2016 Jennifer L. Vande Voort, Elizabeth D. Ballard, David A. Luckenbaugh et al. 67 citations

OBJECTIVE: Insomnia and disrupted sleep are associated with increased risk of suicide. The N-methyl-d-aspartate antagonist ketamine has been associated with reduced suicidal thoughts, but the mechanism of action is unknown. This study sought to evaluate differences in nocturnal wakefulness in depressed individuals who did and did not have an antisuicidal response to ketamine. METHODS:...

Continuation phase intravenous ketamine in adults with treatment-resistant depression.

Journal of Affective Disorders December 2016 Jennifer L. Vande Voort, Robert J Morgan, Simon Kung et al.

Little is known about the antidepressive effects of repeated intravenous ketamine infusions beyond the acute phase of treatment in patients with refractory depression. Twelve subjects with treatment-resistant non-psychotic unipolar or bipolar major depression and suicidal ideation were given repeated (up to 6) thrice-weekly acute-phase intravenous infusions of ketamine (0.5mg/kg, administered...

Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects.

Drug Development Research December 2016 David Feifel

Preclinical Research The surprising results of a small clinical trial on the effects of low dose ketamine, a 65-year old anesthetic drug that is also used off-label for chronic pain and recreationally as a club drug, in eight depressed subjects unleashed the most significant advance in antidepressant drug development in decades. That study and subsequent ones have demonstrated that low dose,...

Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant.

Neuroscience Bulletin December 2016 Weili Zhu, Zengbo Ding, Yinan Zhang et al.

Major depression is a serious psychiatric disorder and remains a leading cause of disability worldwide. Conventional antidepressants take at least several weeks to achieve a therapeutic response and this lag period has hindered their ability to attain beneficial effects in depressed individuals at high risk of suicide. The non-competitive N-methyl-D-aspartate glutamate receptor antagonist...

[Ketamine administration in case of severe, therapy resistant depressed patient, case report].

Ideggyogyaszati szemle November 30, 2016 Szabolcs Morvai, Attila István Nagy, Adrienn Bálint-Szöllősi et al.

Objective - In our case report we present the treatment of a female patient suffering from therapy resistant depression. This procedure is not in practice in Hungary at present, the aim of our work to reproduce the findigs of international studies in domestic circumstances. Matter - Major depression is a common, chronic and severe mental disorder, with 16.2% lifetime prevalence. Many...

Ketamine: 50 Years of Modulating the Mind

Frontiers in Human Neuroscience November 29, 2016 Linda Li, Phillip E. Vlisides 382 citations

Ketamine was introduced into clinical practice in the 1960s and continues to be both clinically useful and scientifically fascinating. With considerably diverse molecular targets and neurophysiological properties, ketamine's effects on the central nervous system remain incompletely understood. Investigators have leveraged the unique characteristics of ketamine to explore the invariant,...

Continuous Social Defeat Induces Depression-Like Symptoms Including Anhedonia and Slowed Time Perception that are Rapidly Reversed by Ketamine

Timing & Time Perception November 26, 2016 Bin Yin, Sven Thönes, Ruey-Kuang Cheng et al.

Male Sprague–Dawley rats were exposed to social defeat and subordination by aggressive male Long–Evans rats. The social defeat procedure involved the continuous exposure to an aggressive resident for 10 days, while living in a protective cage within the resident’s home cage with daily brief confrontations. These stress experiences resulted in 1) reduced body weight; 2) decreased social...

Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.

Progress in Neuro-Psychopharmacology and Biological Psychiatry November 3, 2016 Kristian Gaarn Du Jardin, Heidi Kaastrup Müller, Betina Elfving et al.

A single i.v. infusion of ketamine, classified as an N-methyl-d-aspartate (NMDA) receptor antagonist, may alleviate depressive symptoms within hours of administration in treatment resistant depressed patients, and the antidepressant effect may last for several weeks. These unique therapeutic properties have prompted researchers to explore the mechanisms mediating the antidepressant effects of...

N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.

Progress in Neuro-Psychopharmacology and Biological Psychiatry November 3, 2016 Jen-Cheng Lin, Ming‐huan Chan, Mei-Yi Lee et al.

Ketamine, a dissociative anesthetic, produces rapid and sustained antidepressant effects at subanesthtic doses. However, it still inevitably induces psychotomimetic side effects. N,N-dimethylglycine (DMG) is a derivative of the amino acid glycine and is used as a dietary supplement. Recently, DMG has been found acting at glycine binding site of the N-methyl-d-aspartate receptor (NMDAR). As...

DOI: 10.1016/j.pnpbp.2016.06.002 (opens in new tab) Full text (opens in new tab) Anesthesia Forced swimming Glycine Nmda receptor +1

S-Ketamine Rapidly Reverses Synaptic and Vascular Deficits of Hippocampus in Genetic Animal Model of Depression

The International Journal of Neuropsychopharmacology November 2, 2016 Maryam Ardalan, Gregers Wegener, Ali H. Rafati et al. 38 citations

Background: The neurovascular plasticity of hippocampus is an important theory underlying major depression. Ketamine as a novel glutamatergic antidepressant drug can induce a rapid antidepressant effect within hours. In a mechanistic proof of this concept, we examined whether ketamine leads to an increase in synaptogenesis and vascularization within 24 hours after a single injection in a...

Ketamine: NMDA Receptors and Beyond

Journal of Neuroscience November 2, 2016 Charles F Zorumski, Yukitoshi Izumi, Steven Mennerick 252 citations

Human studies examining the effects of the dissociative anesthetic ketamine as a model for psychosis and as a rapidly acting antidepressant have spurred great interest in understanding ketamine's actions at molecular, cellular, and network levels. Although ketamine has unequivocal uncompetitive inhibitory effects on N-methyl-d-aspartate receptors (NMDARs) and may preferentially alter the...

Molecular Mechanism and Clinical Relevance of Ketamine as Rapid-Acting Antidepressant.

Drug Development Research November 2016 Vesna Pešić, Jelena Petrović, Marin M Jukić

Preclinical Research The emergence of rapid-acting antidepressants such as ketamine has motivated studies aiming to reveal the molecular mechanism of the ketamine antidepressant effect and to enable the clinical application of rapid-acting antidepressants. Here, we provide an overview of studies addressing the antidepressant effects of ketamine in depressed patients and animal models of...

Neurovascular plasticity of the hippocampus one week after a single dose of ketamine in genetic rat model of depression.

Hippocampus November 2016 Maryam Ardalan, Gregers Wegener, Benedetta Polsinelli et al.

Glutamatergic system and the structural plasticity hypothesis are principal components for rapid and sustained antidepressant effects of novel antidepressant therapeutics. This study represents the first investigation of the structural plasticity of the hippocampus as one of the main contributed mechanisms to the sustained anti-depressive effect of ketamine. Flinders Sensitive Line (FSL) and...

Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3

The World Journal of Biological Psychiatry October 10, 2016 Steven F. Grieco, Dmitry Velmeshev, M. Magistri et al.

Abstract Objectives: We examined mechanisms that contribute to the rapid antidepressant effect of ketamine in mice that is dependent on glycogen synthase kinase-3 (GSK3) inhibition. Methods: We measured serotonergic (5HT)-2C-receptor (5HTR2C) cluster microRNA (miRNA) levels in mouse hippocampus after administering an antidepressant dose of ketamine (10 mg/kg) in wild-type and GSK3 knockin mice,...

Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine

The International Journal of Neuropsychopharmacology October 7, 2016 Chao Dong, Ji-Chun Zhang, Wei Yao et al. 116 citations

Background: Similar to the N-methyl-D-aspartate receptor antagonist ketamine, the metabotropic glutamate 2/3 receptor antagonist, MGS0039, shows antidepressant effects. However, there are no reports comparing these 2 compounds in the social defeat stress model of depression. Methods: We examined the effects of MGS0039 (1 mg/kg) and ketamine (10 mg/kg) on depression-like behavior in susceptible...

DOI: 10.1093/ijnp/pyw089 (opens in new tab) Ketamine Dentate gyrus Prefrontal cortex Brain-derived neurotrophic factor +9

Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression.

Progress in Neuro-Psychopharmacology and Biological Psychiatry October 3, 2016 Yong‐Ku Kim, Kyoung-Sae Na

Treatment-resistant depression (TRD) causes substantial socioeconomic burden. Although a consensus on the definition of TRD has not yet been reached, it is certain that classic monoaminergic antidepressants are ineffective for TRD. One decade ago, many researchers found ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, to be an alternative to classic monoaminergic antidepressants....

Repeated ketamine treatment induces sex-specific behavioral and neurochemical effects in mice.

Behavioural Brain Research October 1, 2016 Connor Thelen, Jonathon Sens, Joseph Mauch et al.

One of the most striking discoveries in the treatment of major depression was the finding that infusion of a single sub-anesthetic dose of ketamine induces rapid and sustained antidepressant effects in treatment-resistant depressed patients. However, ketamine's antidepressant-like actions are transient and can only be sustained by repeated drug treatment. Despite the fact that women experience...

Behavioral and biochemical effects of ketamine and dextromethorphan relative to its antidepressant-like effects in Swiss Webster mice

Neuroreport September 28, 2016 Linda Nguyen, Brandon P Lucke-Wold, A. Logsdon et al.

Ketamine has been shown to produce rapid and robust antidepressant effects in depressed individuals; however, its abuse potential and adverse psychotomimetic effects limit its widespread use. Dextromethorphan (DM) may serve as a safer alternative on the basis of pharmacodynamic similarities to ketamine. In this proof-of-concept study, behavioral and biochemical analyses were carried out to...

Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans

Frontiers in Pharmacology September 27, 2016 Sara de la Salle, Joëlle Choueiry, D. Shah et al.

N-methyl-D-aspartate (NMDA) receptor antagonists administered to healthy humans results in schizophrenia-like symptoms, which preclinical research suggests are due to glutamatergically altered brain oscillations. Here, we examined resting-state electroencephalographic activity in 21 healthy volunteers assessed in a placebo-controlled, double-blind, randomized study involving administration of...